Hong Kong approves celebrity weight-loss drug, but experts say it’s not just to look good
The latest celebrity weight-loss drug to be given the nod in Hong Kong will be available in December, but experts cautioned ...
Ozempic’s maker wants the US government to ban cheaper versions of the high-priced $969 injection weight-loss drug – claims the formula is ‘too complex’ to cop…
Critics, including Senator Bernie Sanders, question whether the push to block alternatives is truly about safety — or simply ...
Novo Nordisk Reports Insider Trading Activity
Novo Nordisk (NVO) has released an update. Novo Nordisk, a leading global healthcare company, recently reported that its board members and ...
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers ...
Healthy Returns: Weight loss drug race heats up with pill data from Viking Therapeutics, AstraZeneca
AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...
Investors Like Certainty. Trump's Win Gave Them Some.
Nvidia topping Apple as the most valuable company in the world and joining the Dow Jones Industrial Average. Why Novo Nordisk ...
Business Insider1d
Novo Nordisk’s Strategic Share Repurchase Moves
Novo Nordisk (NVO) has released an update. Novo Nordisk has announced a significant transaction under its 2024 share repurchase program, acquiring 6.31 million B shares from Novo Holdings for DKK 4.74 ...
Becker's Hospital Review1d
3 Ozempic updates: Competition, warnings and potential uses
A Novo Nordisk trial also discovered an association between Wegovy prescriptions and fewer hospitalizations for any cause. In the study, 33.4% of patients taking Wegovy were admitted, compared to ...
FiercePharma1d
While Novo and Lilly's market value declined in Q3, BMS, Gilead and Sanofi surged: GlobalData
Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...